Search results for "KRAS"
showing 10 items of 232 documents
A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer:…
2021
PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site…
Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care.
2016
e15048Background: Dose- and treatment limiting cetuximab-induced skin rash ≥ 3° occur in 18% of colorectal cancer (CRC) patients. Survival, response and toxicity parameters were re-evaluated under a pre-defined skin prophylaxis consistent of vitamin K1 ointment and oral doxycycline. Methods: This is a national, phase IV, multicenter, 1st-line CRC trial (N = 165, KRAS wt, EGFR +, ECOG 0/1) in UICC stage 4 patients. Patients received irinotecan 180 mg/m² (d1) , folinic acid 400 mg/m² (d1), and 5-FU 400 mg/m² (d1, d2) and cetuximab ( 400 mg² (d1), then 250 mg/m² qw). Concurrently, patients received 0.1% vitamin K1 ointment qd and oral doxycycline 100 mg bid. Upon occurrence of rash ≥ 3°, an ad…
KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
2022
Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied the frequency and clinical characteristics in a real-world and population-based setting. Methods: Patients from three Nordic population-based cohorts and the real-life RAXO-study were combined. RAS and BRAF tests were performed in routine healthcare, except for one cohort. The dataset consisted of 2,559 patients, of which 1,871 could be accurately classified as KRAS, NRAS, and BRAF-V600E. Demog…
KRAS-mutated iCCA display distinct molecular alterations and a preferential sensitivity towards PARP-1 inhibition
2021
Sikspārņu rudens migrācijas intensitāte atkarībā no attāluma līdz jūras krastam un no meteoroloģiskajiem apstākļiem
2019
Sikspārņu rudens migrācijas laikā vēja parkos ir novērota liela sikspārņu mirstība. Šīs migrācijas laikā liels skaits sikspārņu migrē gar jūras krastu. Lai pēc iespējas sikspārņu mirstību samazinātu, ir nepieciešams noteikt augsta riska zonas, kurās vēja parkus būvēt nedrīkst, kā arī ir svarīgi spēt paredzēt sikspārņu migrācijas intensitāti pēc meteoroloģiskajiem faktoriem. LU Bioloģijas institūta ornitoloģisko pētījumu stacijā Papē no 11. līdz 25. augustam ar automātiskiem ultraskaņas detektoriem tika ierakstīts sikspārņu nakts pārlidojumu skaits piecos dažādos attālumos no jūras krasta. 74,6 % no visiem pārlidojumiem tika novēroti trīs aktīvākajās migrācijas naktīs, un 46,3 % no visiem pā…
Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: The role of p53 and p21
2008
Cucurbitacins have been shown to inhibit proliferation in a variety of cancer cell lines. The aim of this study was to determine their biological activity in colon cancer cell lines that do not harbor activated STAT3, the key target of cucurbitacin. In order to establish the role of activated kRas in the responsiveness of cells to cucurbitacins, we performed experiments in isogenic colon cancer cell lines, HCT116 and Hke-3, which differ only by the presence of an activated kRas allele. We compared the activity of 23, 24-dihydrocucurbitacin B (DHCB) and cucurbitacin R (CCR), two cucurbitacins that we recently isolated, with cucurbitacin I (CCI), a cucurbitacin with established antitumorigeni…
Krāsu redzes izvērtēšana ar datorizētu krāsu sakārtošanas testu
2022
Darbs ir uzrakstīts latviešu valodā uz 39 lapaspusēm. Tas satur 23 attēlus, 1 tabulu, 5 pielikumus un 30 atsauces uz literatūras avotiem. Mērķis: izvērtēt krāsu redzi ar datorizētu FM-100 nokrāsu testu, dalībniekiem ar un bez krāsu redzes deficītiem. Salīdzināt iegūtos rezultātus ar fizisko testu rezultātiem (D-15 divas versijas, HRR, aomaloskops, FM-100 nokrāsu tests). Pētījumā piedalījās 30 dalībnieki (vīrieši), pusei dalībnieku tika konstatēti krāsu redzes deficīti. Krāsu sakārtošanas testi tika analizēti ar Vingrys and King-Smith metodi. Izanalizējot datorizētā testa rezultātus tika noteiktas vidējās leņķa vērtības katram krāsu redzes deficītu veidam. Atslēgas vārdi: krāsu redzes deficī…
Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.
2014
Abstract Activating KRAS mutations are detected in a substantial number of hematologic malignancies. In a murine T-cell acute lymphoblastic leukemia (T-ALL) model, we previously showed that expression of oncogenic Kras induced a premalignant state accompanied with an arrest in T-cell differentiation and acquisition of somatic Notch1 mutations. These findings prompted us to investigate whether the expression of oncogenic KRAS directly affects DNA damage repair. Applying divergent, but complementary, genetic approaches, we demonstrate that the expression of KRAS mutants is associated with increased expression of DNA ligase 3α, poly(ADP-ribose) polymerase 1 (PARP1), and X-ray repair cross-comp…
Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer
2013
Abstract The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase, which coordinates cell growth, polarity, motility, and metabolism. In non–small cell lung carcinoma, LKB1 is somatically inactivated in 25% to 30% of cases, often concurrently with activating KRAS mutations. Here, we used an integrative approach to define novel therapeutic targets in KRAS-driven LKB1-mutant lung cancers. High-throughput RNA interference screens in lung cancer cell lines from genetically engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led to the identification of Dtymk, encoding deoxythymidylate kinase (DTYMK), which catalyzes dTTP biosynthesis, as synthetica…
Rekomendāciju sistēma optimālākai laika patēriņa kontrolei
2022
Darba ietvaros tika apskatīta rekomendāciju sistēma un prokrastinācija, kas izpaužas kā problemātiska viedtālruņa lietošana. Rekomendāciju sistēmas mūsdienās arvien biežāk tiek veidotas komerciāliem nolūkiem, tādēļ darba mērķis ir pētīt un aprakstīt rekomendāciju sistēmas un to dažādos veidus. Analizējot iegūtos datus no aptaujām izveidot praktisku piemēru rekomendāciju sistēmai un to pielāgot mobilajai lietotnei.